Journal
BLOOD
Volume 131, Issue 17, Pages 1899-1902Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2017-10-784074
Keywords
-
Categories
Funding
- National Institutes of Health, National Heart, Lung, and Blood Institute [P01HL073311, R01 HL096062, R37 HL57506, R01 HL126645]
Ask authors/readers for more resources
Current antithrombotic drugs, including widely used antiplatelet agents and anticoagulants, are associated with significant bleeding risk. Emerging experimental evidence suggests that the molecular and cellular mechanisms of hemostasis and thrombosis can be separated, thereby increasing the possibility of new antithrombotic therapeutic targets with reduced bleeding risk. We review new coagulation and platelet targets and highlight the interaction between integrin alpha(M)beta(2) (Mac-1, CD11b/CD18) on leukocytes and GPIb alpha on platelets that seems to distinguish thrombosis from hemostasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available